News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NicOx SA (NCOX.F) NCX 1510 Partnered With Biolipox AB Demonstrates Rapid Relief In New Clinical Trial



10/19/2005 5:12:47 PM

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Feb. 22, 2005--NicOx S.A. (Eurolist: NICOX) informs you that its partner, Biolipox AB, issued a press release today announcing that a new clinical study of NCX 1510, in development for the treatment of rhinitis, has demonstrated an onset of action of only 5-10 minutes. These new results follow the announcement in June 2004, that NCX 1510 had reached the primary efficacy endpoint of a Phase IIa study in patients suffering from allergic rhinitis. NCX 1510 is the first compound to be selected from the ongoing research and co-development agreement between NicOx and Biolipox for the discovery and development of novel compounds in the respiratory field.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES